Literature DB >> 34406460

[Treatment and management of orbital tumors].

Michael Zimbelmann1, Birte Neppert2, Roya Piria2, Neele Babst2, Katharina A Ponto3, Salvatore Grisanti2, Ludwig M Heindl4,5, Vinodh Kakkassery2.   

Abstract

BACKGROUND: There are various options for the conservative treatment of the most frequent orbital tumors. These can delay, complement or be superior to the surgical approach, which is often prone to complications.
OBJECTIVE: This article gives a summary of the possible treatment options for the most common orbital tumors in childhood and adulthood.
METHODS: A literature search was carried out and the possible treatment pathways are presented.
RESULTS: 1. Frequent orbital tumors in childhood: a systemic treatment with noncardioselective beta blockers is the primary treatment for capillary orbital hemangiomas. In cases of no response, steroids, interferon alpha or cyclophosphamide are treatment options. Observation is a possible option for smaller dermoid cysts, in cases of progression excision can become necessary. Symptomatic optic nerve gliomas can also be observed and in cases of progression treated with chemotherapy, mTOR/MEK inhibitors or radiotherapy (children > 5 years). Rhabdomyosarcomas are biopsied and subsequently treated by radiotherapy and chemotherapy. 2. Frequent orbital tumors in adulthood: asymptomatic cases of cavernous hemangiomas of the orbit can just be observed. Symptomatic hemangiomas can be surgically excised or treated with radiotherapy. For meningiomas of the optic nerve sheath radiotherapy is a very effective treatment. Surgical excision should be reserved for cases with no prognosis of visual acuity. There is also the option to treat with antiprogesterone. Orbital lymphomas with purely orbital involvement can be treated with radiotherapy, chemotherapy or the application of rituximab.
CONCLUSION: There are now very effective conservative treatment options for many orbital tumors. In some cases a surgical procedure can be avoided and a good visual function can be retained.
© 2021. Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Glioma; Hemangioma; Meningioma; Rhabdomyosarcoma; Vision

Mesh:

Year:  2021        PMID: 34406460     DOI: 10.1007/s00347-021-01471-9

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  52 in total

1.  Deep periocular infantile capillary hemangiomas responding to topical application of timolol maleate, 0.5%, drops.

Authors:  Kanmin Xue; Göran Darius Hildebrand
Journal:  JAMA Ophthalmol       Date:  2013-09       Impact factor: 7.389

2.  Propranolol for severe hemangiomas of infancy.

Authors:  Christine Léauté-Labrèze; Eric Dumas de la Roque; Thomas Hubiche; Franck Boralevi; Jean-Benoît Thambo; Alain Taïeb
Journal:  N Engl J Med       Date:  2008-06-12       Impact factor: 91.245

3.  Topical propranolol for infantile haemangiomas: a systematic review.

Authors:  A Price; S Rai; R W J Mcleod; J C Birchall; H A Elhassan
Journal:  J Eur Acad Dermatol Venereol       Date:  2018-05-03       Impact factor: 6.166

4.  Failure of intralesional propranolol in infantile hemangiomas.

Authors:  Mauricio Torres-Pradilla; Eulalia Baselga
Journal:  Pediatr Dermatol       Date:  2013-09-03       Impact factor: 1.588

5.  Oral propranolol for treatment of periocular infantile hemangiomas.

Authors:  Tara G Missoi; Gregg T Lueder; Kenneth Gilbertson; Susan J Bayliss
Journal:  Arch Ophthalmol       Date:  2011-03-14

Review 6.  Ophthalmic issues in hemangiomas of infancy.

Authors:  Emily Ceisler; Francine Blei
Journal:  Lymphat Res Biol       Date:  2003       Impact factor: 2.589

Review 7.  Initiation and use of propranolol for infantile hemangioma: report of a consensus conference.

Authors:  Beth A Drolet; Peter C Frommelt; Sarah L Chamlin; Anita Haggstrom; Nancy M Bauman; Yvonne E Chiu; Robert H Chun; Maria C Garzon; Kristen E Holland; Leonardo Liberman; Susan MacLellan-Tobert; Anthony J Mancini; Denise Metry; Katherine B Puttgen; Marcia Seefeldt; Robert Sidbury; Kendra M Ward; Francine Blei; Eulalia Baselga; Laura Cassidy; David H Darrow; Shawna Joachim; Eun-Kyung M Kwon; Kari Martin; Jonathan Perkins; Dawn H Siegel; Robert J Boucek; Ilona J Frieden
Journal:  Pediatrics       Date:  2012-12-24       Impact factor: 7.124

8.  SubTenon's infusion of steroids for treatment of orbital hemangiomas.

Authors:  David K Coats; James W O'Neil; Vincent J D'Elia; Kathryn M Brady-McCreery; Evelyn A Paysse
Journal:  Ophthalmology       Date:  2003-06       Impact factor: 12.079

9.  Evaluation of intralesional propranolol for periocular capillary hemangioma.

Authors:  Ahmed Awadein; Mohamed A Fakhry
Journal:  Clin Ophthalmol       Date:  2011-08-15

10.  To compare intralesional and oral propranolol for treating periorbital and eyelid capillary hemangiomas.

Authors:  Aditi Mehta; Mandeep S Bajaj; Neelam Pushker; Bhavna Chawla; Amar Pujari; Sartaj S Grewal; Satinder Pal Singh Grewal; Simar Rajan Singh; Alisha Kishore; Neha Singh Yadav
Journal:  Indian J Ophthalmol       Date:  2019-12       Impact factor: 1.848

View more
  1 in total

1.  [Orbital tumors : Diseases with a maximum challenge for interdisciplinary diagnostics, treatment and aftercare].

Authors:  Vinodh Kakkassery
Journal:  Ophthalmologe       Date:  2021-10-05       Impact factor: 1.059

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.